- Home
- ALXO vs SGA Comparison
ALXO vs SGA Comparison
Compare ALXO & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- SGA
- Stock Information
- Founded
- ALXO 2015
- SGA 1986
- Country
- ALXO United States
- SGA United States
- Employees
- ALXO N/A
- SGA N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- SGA Broadcasting
- Sector
- ALXO Health Care
- SGA Consumer Discretionary
- Exchange
- ALXO Nasdaq
- SGA Nasdaq
- Market Cap
- ALXO 93.7M
- SGA 78.8M
- IPO Year
- ALXO 2020
- SGA 1992
- Fundamental
- Price
- ALXO $1.26
- SGA $12.32
- Analyst Decision
- ALXO Strong Buy
- SGA
- Analyst Count
- ALXO 6
- SGA 0
- Target Price
- ALXO $3.30
- SGA N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- SGA 5.8K
- Earning Date
- ALXO 11-07-2025
- SGA 11-06-2025
- Dividend Yield
- ALXO N/A
- SGA 8.30%
- EPS Growth
- ALXO N/A
- SGA N/A
- EPS
- ALXO N/A
- SGA 0.33
- Revenue
- ALXO N/A
- SGA $110,350,000.00
- Revenue This Year
- ALXO N/A
- SGA N/A
- Revenue Next Year
- ALXO N/A
- SGA $5.37
- P/E Ratio
- ALXO N/A
- SGA $36.79
- Revenue Growth
- ALXO N/A
- SGA N/A
- 52 Week Low
- ALXO $0.40
- SGA $10.75
- 52 Week High
- ALXO $2.27
- SGA $14.27
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- SGA 41.81
- Support Level
- ALXO $1.49
- SGA $11.89
- Resistance Level
- ALXO $1.64
- SGA $12.65
- Average True Range (ATR)
- ALXO 0.14
- SGA 0.27
- MACD
- ALXO -0.05
- SGA -0.05
- Stochastic Oscillator
- ALXO 4.13
- SGA 10.79
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.